Population variation in anti-S. aureus IgG isotypes influences surface protein A mediated immune subversion

Vaccine

Volumn 34, Issue 15, 2016, Pages 1792-1799

  Whitehouse, Julia ^a   Flaxman, Amy ^a   Rollier, Christine ^b   O'Shea, Matthew K ^a,c   Fallowfield, Joanne ^d   Lindsay, Michael ^d   Gunner, Frances ^d   Knox, Kyle ^b   Wyllie, David H ^a,e   Yamaguchi, Yuko ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d INSTITUTE OF NAVAL MEDICINE   (United Kingdom)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Antibody; Immunosenescence; Protein A; Staphylococcus aureus; Vaccine

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; MEMBRANE ANTIGEN; MEMBRANE PROTEIN; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BACTERIUM ADHERENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPRECIPITATION; IMMUNOSENESCENCE; MALE; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; AGED; AGING; BLOOD; COHORT ANALYSIS; HL-60 CELL LINE; IMMUNE EVASION; IMMUNOLOGY; MIDDLE AGED; NORMAL HUMAN; PHAGOCYTOSIS; SEROEPIDEMIOLOGY; YOUNG ADULT;

ADULT; AGED; AGING; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTHY VOLUNTEERS; HL-60 CELLS; HUMANS; IMMUNE EVASION; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PHAGOCYTOSIS; SEROEPIDEMIOLOGIC STUDIES; STAPHYLOCOCCUS AUREUS; YOUNG ADULT;

EID: 84959515156     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.02.034     Document Type: Article

References (44)

1. Williams R.E. Healthy carriage of Staphylococcus aureus: its prevalence and importance. Bacteriol Rev 1963, 27:56-71.
2. Kluytmans J., van Belkum A., Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997, 10(3):505-520.
3. Lowy F.D. Staphylococcus aureus infections. N Engl J Med 1998, 339(8):520-532.
4. Wertheim H.F., Vos M.C., Ott A., van Belkum A., Voss A., Kluytmans J.A., et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 2004, 364(9435):703-705.
5. Klevens R.M., Morrison M.A., Nadle J., Petit S., Gershman K., Ray S., et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007, 298(15):1763-1771.
6. Laupland K.B., Lyytikainen O., Sogaard M., Kennedy K.J., Knudsen J.D., Ostergaard C., et al. The changing epidemiology of Staphylococcus aureus bloodstream infection: a multinational population-based surveillance study. Clin Microbiol Infect 2013, 19(5):465-471.
7. WHO Antimicrobial Resistance Fact sheet No. 194 2015, [April].
8. Moran G.J., Krishnadasan A., Gorwitz R.J., Fosheim G.E., McDougal L.K., Carey R.B., et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006, 355(7):666-674.
9. Spaan A.N., Surewaard B.G., Nijland R., van Strijp J.A. Neutrophils versus Staphylococcus aureus: a biological tug of war. Annu Rev Microbiol 2013, 67:629-650.
10. van Kessel K.P., Bestebroer J., van Strijp J.A. Neutrophil-mediated phagocytosis of Staphylococcus aureus. Front Immunol 2014, 5:467.
11. Kim H.K., Emolo C., DeDent A.C., Falugi F., Missiakas D.M., Schneewind O. Protein A-specific monoclonal antibodies and prevention of Staphylococcus aureus disease in mice. Infect Immun 2012, 80(10):3460-3470.
12. Fowler V.G., Proctor R.A. Where does a Staphylococcus aureus vaccine stand?. Clin Microbiol Infect 2014, 20(Suppl 5):66-75.
13. Nissen M., Marshall H., Richmond P., Shakib S., Jiang Q., Cooper D., et al. A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults. Vaccine 2015, 33(15):1846-1854.
14. Fattom A., Matalon A., Buerkert J., Taylor K., Damaso S., Boutriau D. Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: phase III randomized study. Hum Vaccines Immunother 2015, 11(3):632-641.
15. Dryla A., Prustomersky S., Gelbmann D., Hanner M., Bettinger E., Kocsis B., et al. Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients. Clin Diagn Lab Immunol 2005, 12(3):387-398.
16. Verkaik N.J., Lebon A., de Vogel C.P., Hooijkaas H., Verbrugh H.A., Jaddoe V.W., et al. Induction of antibodies by Staphylococcus aureus nasal colonization in young children. Clin Microbiol Infect 2010, 16(8):1312-1317.
17. Colque-Navarro P., Jacobsson G., Andersson R., Flock J.I., Mollby R. Levels of antibody against 11 Staphylococcus aureus antigens in a healthy population. Clin Vaccine Immunol 2010, 17(7):1117-1123.
18. Gillis C., Gouel-Cheron A., Jonsson F., Bruhns P. Contribution of human FcγRs to disease with evidence from human polymorphisms and transgenic animal studies. Front Immunol 2014, 5:254.
19. Vidarsson G., Dekkers G., Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 2014, 5:520.
20. Woof J.M., Burton D.R. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol 2004, 4(2):89-99.
21. Roos D., van Bruggen R., Meischl C. Oxidative killing of microbes by neutrophils. Microbes Infect 2003, 5(14):1307-1315.
22. Walport M.J. Complement. First of two parts. N Engl J Med 2001, 344(14):1058-1066.
23. Shopsin B., Gomez M., Montgomery S.O., Smith D.H., Waddington M., Dodge D.E., et al. Evaluation of protein A gene polymorphic region DNA sequencing for typing of Staphylococcus aureus strains. J Clin Microbiol 1999, 37(11):3556-3563.
24. Kronvall G., Williams R.C. Differences in anti-protein A activity among IgG subgroups. J Immunol 1969, 103(4):828-833.
25. Peterson P.K., Verhoef J., Sabath L.D., Quie P.G. Effect of protein A on staphylococcal opsonization. Infect Immun 1977, 15(3):760-764.
26. Silverman G.J., Goodyear C.S. Confounding B-cell defences: lessons from a staphylococcal superantigen. Nat Rev Immunol 2006, 6(6):465-475.
27. Van Loghem E., Frangione B., Recht B., Franklin E.C. Staphylococcal protein A and human IgG subclasses and allotypes. Scand J Immunol 1982, 15(3):275-278.
28. Miller R.R., Walker A.S., Godwin H., Fung R., Votintseva A., Bowden R., et al. Dynamics of acquisition and loss of carriage of Staphylococcus aureus strains in the community: the effect of clonal complex. J Infect 2014, 68(5):426-439.
29. van Diemen P.M., Yamaguchi Y., Paterson G.K., Rollier C.S., Hill A.V., Wyllie D.H. Irradiated wild-type and Spa mutant Staphylococcus aureus induce anti-S. aureus immune responses in mice which do not protect against subsequent intravenous challenge. Pathog Dis 2013, 68(1):20-26.
30. McDevitt D., Francois P., Vaudaux P., Foster T.J. Identification of the ligand-binding domain of the surface-located fibrinogen receptor (clumping factor) of Staphylococcus aureus. Mol Microbiol 1995, 16(5):895-907.
31. Burbelo P.D., Goldman R., Mattson T.L. A simplified immunoprecipitation method for quantitatively measuring antibody responses in clinical sera samples by using mammalian-produced Renilla luciferase-antigen fusion proteins. BMC Biotechnol 2005, 5:22.
32. Kim H.K., Cheng A.G., Kim H.Y., Missiakas D.M., Schneewind O. Nontoxigenic protein A vaccine for methicillin-resistant Staphylococcus aureus infections in mice. J Exp Med 2010, 207(9):1863-1870.
33. Romero-Steiner S., Libutti D., Pais L.B., Dykes J., Anderson P., Whitin J.C., et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997, 4(4):415-422.
34. Amigorena S., Salamero J., Davoust J., Fridman W.H., Bonnerot C. Tyrosine-containing motif that transduces cell activation signals also determines internalization and antigen presentation via type III receptors for IgG. Nature 1992, 358(6384):337-341.
35. Sokolovska A., Becker C.E., Stuart L.M. Measurement of phagocytosis, phagosome acidification, and intracellular killing of Staphylococcus aureus. Current protocols in immunology 2012, [Chapter 14:Unit 14.30]. J.E. Coligan (Ed.).
36. Ko Y.P., Kuipers A., Freitag C.M., Jongerius I., Medina E., van Rooijen W.J., et al. Phagocytosis escape by a Staphylococcus aureus protein that connects complement and coagulation proteins at the bacterial surface. PLoS Pathog 2013, 9(12):e1003816.
37. Gordon D.L., Rice J.L. Opsonin-dependent and independent surface phagocytosis of S. aureus proceeds independently of complement and complement receptors. Immunology 1988, 64(4):709-714.
38. Lamagni T.L., Potz N., Powell D., Pebody R., Wilson J., Duckworth G. Mortality in patients with meticillin-resistant Staphylococcus aureus bacteraemia, England 2004-2005. J Hosp Infect 2011, 77(1):16-20.
39. Goronzy J.J., Weyand C.M. Understanding immunosenescence to improve responses to vaccines. Nat Immunol 2013, 14(5):428-436.
40. Gibson K.L., Wu Y.C., Barnett Y., Duggan O., Vaughan R., Kondeatis E., et al. B-cell diversity decreases in old age and is correlated with poor health status. Aging Cell 2009, 8(1):18-25.
41. Gagliardi A.M., Gomes Silva B.N., Torloni M.R., Soares B.G. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev 2012, 10:Cd008858.
42. Yates N.L., Liao H.X., Fong Y., deCamp A., Vandergrift N.A., Williams W.T., et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med 2014, 6(228):228ra39.
43. Nordenfelt P., Waldemarson S., Linder A., Morgelin M., Karlsson C., Malmstrom J., et al. Antibody orientation at bacterial surfaces is related to invasive infection. J Exp Med 2012, 209(13):2367-2381.
44. Wenisch C., Patruta S., Daxbock F., Krause R., Horl W. Effect of age on human neutrophil function. J Leukoc Biol 2000, 67(1):40-45.